{"prompt": "['Novartis', 'Confidential', 'Page 10', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'a positive reversibility test or a historic positive reversibility test performed', 'according to ATS/ERS guidelines will be acceptable at V101', 'Provided detailed instructions for the investigator regarding the need to pause or', 'terminate concomitant medication for patient randomization into the trial, Section', '5.5.8 Prohibited Medications and Table 5-3 Prohibited Medications', 'Clarified definition of the end of the trial, Section 5.6.1', 'Added serum total IgE and antigen-specific IgE (ImmunoCAP) assessments at run-in', 'phase Table 6-1 Assessment Schedule', 'Added spirometry at Trial Discontinuation (TD) visit as Spirometry is part of the', 'ACQ-7 assessment, Table 6-1 Assessment Schedule', 'Removed central review of ECGs by central laboratory and requirement to print', 'tracings in duplicate, Section 6.5.5', 'Described measures for data protection to avoid unauthorized access, to ensure', 'confidentiality of records and to prevent security breach Section 8.2', 'Removed the key secondary variable (change in trough FEV1 from baseline to week', '24) using only the primary variable for hypotheses testing and adjusting for', 'multiplicity. Testing strategy has been changed from global Simes test to trimmed', 'Simes test, Sections 9.4.1, 9.4.2, 9.4.3, 9.4.4,and 9.4.5', 'Included the change in trough FEV1 from baseline to week 24 as one of the secondary', 'variables and the corresponding analysis, Section 9.5.1.2', 'Changed the sample size calculations and power adjustments based on updated testing', 'strategy of using only the primary endpoint, Section 9.8', 'Corrected for consistency throughout document; updated formatting, typographical', 'errors', 'Amendment 1', 'Amendment rationale', 'The primary reasons for this amendment are to ensure consistency across sections of the', 'protocol and to update drug supply sourcing strategies and operational details/processes.', 'Protocol sections have been harmonized with respect to the escalation and de-escalation of', 'controller or maintenance therapy allowed during the treatment period. The drug supply', 'sourcing strategy is updated as local sourcing for the comparative treatment arm', '(salmeterol/fluticasone and tiotropium) and the run-in medication (salmeterol/futicasone)', 'may occur, in addition to global sourcing.', 'Recruitment for the study has not initiated as of time of protocol amendment finalization.', 'These changes will not influence the study population, the results of the study nor is there any', 'impact to subject safety.', 'Changes to the protocol', 'Changed formatting of inclusion criteria 1-7 with numeric numbering of criteria from', 'bullets for internal consistency (Section 4.1).']['Novartis', 'Confidential', 'Page 11', 'Amended Protocol Version v02/Clean', 'Protocol No. CQVM149B2306', 'Corrected error for exclusion criteria 19, ECG to be performed at Visit 101 and not V1', '(Section 4.2).', 'Corrected typo for exclusion 26, patients on maintenance immunotherapy for allergies for', 'less than 3 months; changed \"or\" to \"for\" (Section 4.2).', 'Added open-label comparative treatments (salmeterol/fluticasone and tiotropium) and', 'run-in medication (salmeterol/fluticasone) which may be sourced locally from', 'commercial supplies. (Section 5.1.1 and Section 5.1.2)', 'Clarified that packaging with 2 part labeling is applicable for globally sourced', 'treatments; all labeling will comply with local regulations (Section 5.5.2)', 'Removed SmPC (Summary of Product Characteristics) as a reference for appropriate use', 'of step-up and step-down therapy; refer to local approved label (Section 5.5.5)', 'Added footnote to Table 5-4, \"Medications allowed under certain circumstances\" to align', \"with Section 5.5.5 which describes the step-up and/or step down of patient's background\", 'medication (controller or maintenance) treatment options allowed during the treatment', 'phase of the trial. (Section 5.5.8)', 'Provided clarification that patients will be instructed by Investigators to contact the trial', 'site when patient receives eDiary notifications when asthma worsening criteria is met.', '(Section 6.4.4).', 'Added description of the baseline reference for SABA use in run-in and treatment', 'periods (Section 6.4.4).', 'Aligned protocol sections with updated regional stratification and statistical analysis plan', '(Section 9).']\n\n###\n\n", "completion": "END"}